Opioid Use Disorder (OUD) Market Size, Share & Covid-19 Impact Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2020-2027

The global opioid use disorder (OUD) market size was USD 2.81 billion in 2019 and is projected to reach USD 4.87 billion by 2027, exhibiting a CAGR of 8.7% during the forecast period.

We are in process of revamping Opioid Use Disorder (OUD) Market with respect to COVID-19 Impact.

Request Sample

As the number of patients suffering from chronic pain increases worldwide, the number of prescriptions for painkillers, which often contains opioids, is expected to surge. However, as the consumption of these opioid-based painkillers reduce the patient’s pain, the dependency or addiction to these medications increases. This addiction has fatal consequences, as the overdose of opioids can lead to death or permanent impairment of the individual’s normal psychological and physiological functioning.

To mitigate the risk, governments worldwide, such as the U.S., have implemented policies to tackle this condition effectively. Such policy initiatives, coupled with the increasing product launches by key players, are expected to drive the market positively.

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth

The coronavirus pandemic has had a varied impact on the pharmaceutical market, ranging from positive to negative, based on the demand. There has been a negative impact on certain medications, owing to a decline in their demand due to the lack of visits to healthcare facilities such as hospitals and clinics. Furthermore, to restrain the number of coronavirus cases, several governments have implemented strict nationwide lockdown. This has led to a sharp decline in the flow of patients across hospital settings. Moreover, the cancellation or postponement of non-essential medical procedures has further led to a negative impact on market growth.

In the OUD market, the number of patients suffering from opioid overdoses and relapses in their addiction sharply increased during this period. However, in the case of prominent companies engaged in the opioid use disorder market, such as Indivior, the companies experienced a sharp decline in their product revenues during this period. This rapid decline in sales has been due to the COVID-19 related disruptions. Thus, the global market for opioid use disorder is expected to experience a negative impact.

LATEST TRENDS

Request a Free sample to learn more about this report.

Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth

One of the upcoming trends witnessed in the global market in treating opioid addiction is the increasing usage of buprenorphine treatment patches as an effective therapy. Buprenorphine patches are considered to be a novel approach for the treatment of opioid use disorder. The usage of transdermal patches has various advantages over other treatment modes such as injections as it is the most comfortable mode of drug delivery, which effectively reduces the pain and can be self-administered by the patient. Furthermore, these transdermal patches can act as a potential alternative for patients requiring around-the-clock opioid therapy for opioid use disorder.

For instance, WellSpan Health, a major U.S. based healthcare system, collaborated with York Opioid Collaborative to establish a clinical trial and reached phase IV in the development of Lidocaine patch for the indication of OUD treatment. This is expected to boost the adoption of treatment on a broader scale. Moreover, the greater inclusion of new patients is anticipated to lead to the opioid use disorder market during the forecast period.

DRIVING FACTORS

Increasing Cases of Opioid Addiction to Drive Market Growth

In the current scenario, the general population suffers from a wide range of severe and chronic diseases, including cancer, cardiovascular, pain arising from injuries, and other conditions. These diseases often cause chronic pain amongst the patients that are managed with the consumption of painkillers, mostly opioids. While the pain reduces, there is a greater chance that the patient may get addicted to these drugs. The growing dependency on these drugs and abrupt discontinuation may lead to the patient suffering from withdrawal symptoms. Hence, the patients continue to use these opioids that sharply increases the probability of fatal consequences for the patients, such as death from an opioid overdose.

According to the American Psychiatric Association (APA), in 2017, an estimated 72,000 Americans died from drug overdoses, including prescription opioids, a 2-fold increase in a decade. Also, patient awareness has considerably increased, owing to such alarming patient statistics. Hence, the increasing cases of opioids dependency are projected to boost the market growth during the forecast period.

Increasing Engagement by Governmental & Non-Governmental Institutions to Aid Market Growth

Another critical driving factor that is expected to boost market growth during the forecast period is the increasing involvement of governmental and non-governmental agencies. The number of individuals suffering from opioid addiction has substantially increased, and it has led several governments to get involved on a wider scale to tackle this crisis.

For instance, the U.S. has one of the largest pools of patients suffering from opioid dependency. This led the United States Department of Health & Human Services (HHS) in 2017 to declare the opioid crisis as a public health emergency. Hence, for tackling this epidemic, the HHS issued a 5 Point Strategy’ to combat the problem. These initiatives are expected to drive the number of individuals opting for treatment suffering from the increasing consumption of opioid-induced drugs. Such factors are expected to positively impact the opioid use disorder (OUD) market during the forecast period.

RESTRAINING FACTORS

Adverse Effects of OUD Drugs to Restrain Market Growth

One of the most critical restraining factors that are anticipated to limit the growth of the global market during the forecast period is the side effects that may arise from the drugs administered for the treatment of opioid addiction. Some of the typical adverse reactions from these drugs include vomiting, bladder pain, abdominal cramps, diarrhea, respiratory issues, bone/joint pain, muscle aches, and constipation. Furthermore, in certain severe cases of adverse reactions, the patient may also suffer from psychological problems such as depression.

In some instances, the usage of SUBOXONE for the treatment of opioid dependency may lead to fast or irregular heartbeat and hyperventilation. Hence, such side effects of these drugs are expected to hinder the market growth during the forecast period.

SEGMENTATION

By Drug Class Analysis

To know how our report can help streamline your business, Speak to Analyst

Buprenorphine to Grow at Faster Pace

Based on drug class, the market includes buprenorphine, methadone, and naltrexone.

The buprenorphine segment accounts for the largest share of the market in 2019. The dominance is due to the greater adoption of these drugs in the developed markets such as the United States and France, coupled with several branded products under this segment. Some essential buprenorphine products include SUBLOCADE, SUBOXONE, and ZUBSOLV.

The methadone segment is anticipated to register a lower growth rate due to the increasing influx of generic product offerings and the comparative lack of new product launches in this segment.

The naltrexone segment is anticipated to register a lower market share during the forecast period due to the comparatively limited number of product offerings.

By Route of Administration Analysis

Parenteral Segment Accounted for the Highest Market Share

Based on the route of administration, the market is segmented into oral and parenteral.

The parenteral segment is projected to account for the highest market share during the forecast period because of the various types of OUD drugs in different dosages in the parenteral form. Hence, this type of drug administration maintains dominance over the global market.

The oral segment is projected to account for a lower share of the global market. However, it is expected to experience significant growth due to many individuals opting for oral administration of drugs compared to the injection of drugs.

By Distribution Channel Analysis

Hospital Pharmacies Segment Dominated the Market in 2019

Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies & stores, and online pharmacies.

The hospital pharmacies segment is anticipated to account for a higher share of the global market because of the dependency of the patient population on these settings for the administration of parenteral OUD drugs such as buprenorphine.

The retail pharmacies & stores segment accounts for the second largest segment during the forecast period due to the dependency on the patient population on these locations for the filling up of prescriptions.

The online pharmacies segment is projected to grow at the highest CAGR as an increasing number of patients have started using online pharmacies as a means of acquiring their drugs owing to the convenience attached to these settings.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

In terms of region, the global market can be segmented into North America, Europe, Asia Pacific, and Rest of the World.

North America market stood at USD 2.16 billion in 2019. The region is anticipated to be dominant during the forecast period owing to the substantial number of individuals in the United States suffering from opioid dependency, the presence of prominent players in the region, and the increasing involvement of the government in tackling the epidemic. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in 2020, it was estimated that in the United States, approximately 2.1 million individuals suffer from opioid use disorders.

Europe is projected to hold the second position in the market. This is attributable to the increasing number of new product launches in the region and the rising number of patients suffering from opioid dependency.

Asia Pacific market is projected to register the strongest CAGR during the forecast period due to the increasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely to favor the growth of the market in the region.

The rest of the world consists of regions such as Latin America and the Middle East & Africa that accounted for a lower share of the market in the past. However, the increasing number of patients suffering from opioid dependency, expanding healthcare expenditure, and the growing awareness amongst the general population is expected to boost the market growth in the forthcoming years.

KEY INDUSTRY PLAYERS

Robust and Diversified Product Portfolio of Indivior PLC, Alkermes, and Orexo AB Has Led to Their Market Dominance

In terms of the competition scenario, certain prominent companies who exert dominance over the global market include Indivior PLC, Alkermes, and Orexo AB. The competitive landscape reflects these players' dominance due to their strong product portfolio in terms of the product offerings of buprenorphine and naltrexone. Furthermore, these companies are engaged in continuous R&D for the development of more effective drugs for the treatment of opioid dependencies, such as long-acting buprenorphine.

For instance, Indivior PLC has many buprenorphine product offerings in its product portfolio, including SUBLOCADE and SUBOXONE. Other vital players in the OUD industry include Orexo AB and Alkermes, known for their extensive product offerings. These companies adopting various strategies such as collaboration and new product launches are anticipated to contribute to their efforts to expand their market share in terms of revenue during the forecast period.

LIST OF KEY MARKET PLAYERS PROFILED:

• Indivior PLC (Chesterfield, U.S.)


• Alkermes (Dublin, Ireland)


• Orexo AB (Uppsala, Sweden)


• Titan Pharmaceuticals, Inc. (South San Francisco, U.S.)


• Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)


• Mallinckrodt Pharmaceuticals (Staines-Upon-Thames, U.K.)


• BioDelivery Sciences International Inc. (Raleigh, U.S.)


• Viatris Inc. (Mylan N.V.) (Canonsburg, U.S.)


• Pfizer, Inc. (New York City, U.S.)


• Hikma Pharmaceuticals PLC (London, U.K.)


• Camurus (Lund, Sweden)


• Other Players

KEY INDUSTRY DEVELOPMENTS: 

• June 2020 – Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the US and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.


• February 2019 – Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favorable ruling in patent litigation.

REPORT COVERAGE

An Infographic Representation of Opioid Use Disorder (OUD) Market

View Full Infographic

To get information on various segments, share your queries with us

The global opioid use disorder (OUD) market research report provides a detailed analysis of the market. It focuses on key aspects such as key industry developments - mergers, acquisitions, partnerships, pipeline analysis-key products, new product launches, statistics of opioid use disorder by key countries/region, and impact of COVID-19 on the market. Besides this, the report offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the global market over recent years.

Report Scope & Segmentation